前往化源商城

57717-97-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-antagonist-CTF
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive SPA70 (final concentration range of 2.8 nM to 92uM for the antagonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of RIF (final concentration of 2uM) in the antagonist mode, using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent antagonists are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Inhibitor10.153140.755621Partial curve; partial efficacy-4.99340.40.7519-22.755618-2.20 0 0 0 0 0 0 0 0 0 0 0-18.96314.228615.423221.78321.990312.7098.251211.76180.02953.02123.5483.2806-18.963QC'd by NCI-NPB
Inhibitor70.794641.186310Single point of activity-4.153.06540.7616-40.68630.5-30 0 0 0 0 0 0 0 0 0 0 0-30.5719-5.82211.70573.85692.3906-3.0434-5.1259-0.0204-4.50967.67922.2068-0.8314-30.5719QC'd by SigmaAldrich
Inhibitor20.258137.67710Partial curve; partial efficacy; poor fit-4.69340.60.8367-32.1775.5-2.40 0 0 0 0 0 0 0 0 0 0 0-23.48087.31197.43618.07377.8115-1.654-1.67136.0557-3.6601-2.9743-2.3177-14.0308-23.4808QC'd by NCI-NPB
Inhibitor16.091637.601210Partial curve; partial efficacy; poor fit-4.79341.13410.8452-30.60127-2.40 0 0 0 0 0 0 0 0 0 0 0-24.2519.691212.09586.967813.07042.3816-4.34997.21867.4852.3057-3.9474-15.5947-24.251QC'd by NCI-NPB
Inactive0-5.54.95490.59534.5-6.942940 0 0 0 0 0 0 0 0 0 0 05.5505-12.581-3.6735-0.3298-5.7361-15.7857-1.8915-7.6677-3.58716.49081.87073.07685.5505QC'd by NIEHS
Inactive0-5.34.95490.51875.50.001740 0 0 0 0 0 0 0 0 0 0 03.4570.4546-1.44463.17460.2283-1.07621.529-0.8791-2.08193.819910.29192.23513.457QC'd by Labotest
Inactive000414.77677.975815.1119.93217.842411.36965.53624.83674.11242.91079.735117.294514.7767QC'd by Microsource
Inactive00047.48485.14659.28654.05173.33396.02881.82297.78417.71411.52646.27186.01687.4848QC'd by SigmaAldrich
Inactive0-4.44.95490.4225-2.299911.540 0 0 0 0 0 0 0 0 0 0 0-0.249911.032112.73438.29587.7656.439510.40716.53437.858915.144413.27616.7991-0.2499QC'd by FLUKA
Inactive00044.71299.82915.22989.11547.79320.69023.11126.00811.17723.21623.76586.64644.7129QC'd by Timtec
Inactive0-5.21.34430.52729-4.545640 0 0 0 0 0 0 0 0 0 0 08.55970.32651.3817-2.9939-6.7498-13.3714-9.4912-0.51632.79663.1192-0.47189.56148.5597QC'd by ASDI
Inactive0004-3.5795-4.3598-0.5776-3.2591-6.8076-5.0883-8.613-3.3668-6.4244-6.5159-4.2276-4.6923-3.5795QC'd by SigmaAldrich
Inactive0004-13.4251-8.7965-1.2528-9.2469-7.9021-3.3764-1.4523-13.4156-8.74672.7588-1.4294-13.8991-13.4251QC'd by Enamine
Inactive0004-9.8167-11.8528-7.2424-12.0513-7.4969-8.9732-12.2154-12.0728-9.5269-6.1546-3.8393-4.0575-9.8167QC'd by Enamine
Inactive0-51.92820.56798-1.469940 0 0 0 0 0 0 0 0 0 0 06.0779-0.0024-0.20133.1935-0.4054-9.5582-2.4938-2.18322.51884.45953.186311.92486.0779QC'd by Enamine
Inactive0-5.354.95490.76345.5-5.365240 0 0 0 0 0 0 0 0 0 0 06.0484-8.1291-5.3769-2.77281.7572-8.221-7.0739-5.55873.9782.57455.20226.39186.0484QC'd by SIGMA
Inactive0-4.451.10.5944321.51440 0 0 0 0 0 0 0 0 0 0 19.85350.7672-4.57174.81875.40172.6732-2.94765.81258.301312.52973.147124.82849.8535QC'd by SIGMA
Inactive0-5.350.60.65698.5-6.764740 0 0 0 0 0 0 0 0 0 0 04.5331-5.4295-8.5539-2.72830.1802-7.8806-0.2857-2.14165.38450.02812.39559.85114.5331QC'd by LightBiologicals
Inactive0004-5.3594-8.871-12.8425-6.6113-4.5224-10.2103-10.3208-6.0527-14.4677-12.9358-16.9058-11.3122-5.3594QC'd by SIGMA
Inactive0-4.351.13410.555112-1.306940 0 0 0 0 0 0 0 0 0 0 08.9371-6.0891-1.9072-0.54095.0417-4.9288-1.0154-0.45852.45211.48640.16.07468.9371QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-antagonist-ONEGlo
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive SPA70 (final concentration range of 2.8 nM to 92uM for the antagonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of RIF (final concentration of 2uM) in the antagonist mode, using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent antagonists are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Inhibitor0.064134.705122Complete curve; partial efficacy-7.19340.80.8198-15.205119.5-1.20 0 0 0 0 0 0 0 0 0 0 0-18.427412.341830.693411.06878.702711.1596-4.0097-0.7424-17.7591-18.9041-6.35-11.9997-18.4274QC'd by NCI-NPB
Inhibitor0.057143.182922Complete curve; partial efficacy-7.24340.30.8029-17.182926-1.20 0 0 0 0 0 0 0 0 0 0 11.79619.343712.079420.15979.87981.19632.351-1.4583-2.3569-9.52431.5791-17.65241.796QC'd by NCI-NPB
Inhibitor1044.889521Partial curve; partial efficacy-50.50.7545-32.389512.5-2.20 0 0 0 0 0 0 0 0 0 0 0-24.45936.37118.740215.923510.6417-2.33847.0423-0.518-9.6117-3.1015-13.119-5.0111-24.4593QC'd by Specs
Inhibitor25.1189202.453110Single point of activity-4.64.95490.8549-206.4531-4-30 0 0 0 0 0 0 0 0 1 0 0-157.118-4.9883-9.5737-8.2214-6.9034-18.4403-0.8015-24.8599-8.40283.7254107.134129.6841-157.118QC'd by Analyticon
Inhibitor5.011944.96610Partial curve; partial efficacy; poor fit-5.30.40.7248-41.4663.5-2.40 0 0 0 0 0 0 0 0 0 0 0-23.2895.976-6.5685-4.0459-5.1171-3.6133-8.2625-11.6513-11.3707-17.7211-9.4112-34.555-23.289QC'd by Analyticon
Inhibitor10Single point of activity00-3-31.2598-4.64091.1143-7.1165-26.93820.15-13.91455.77672.71096.231732.3237-10.1053-31.2598QC'd by SIGMA
Inhibitor57.095176.982710Single point of activity-4.24344.95490.8136-167.97549.0073-30 0 0 1 0 0 0 1 0 0 0 0-125.3564-2.5428-0.74036.0074-119.4048-11.1656-3.8852-1.9563-143.01776.318137.620550.1208-125.3564QC'd by NCI-NPB
Inhibitor28.615381.180810Partial curve; partial efficacy; poor fit-4.54342.72020.7315-71.96919.2117-2.40 0 0 0 0 0 0 0 1 0 0 0-65.0709-9.34540.0654-8.67176.944226.239712.80327.63739.597675.75736.8623-21.7124-65.0709QC'd by NCI-NPB
Inhibitor28.6153146.918310Single point of activity-4.54344.95490.9263-140.53826.3801-30 0 0 0 0 0 0 0 0 1 1 0-138.6637-0.54878.3171-2.0665.2057-1.8734-6.119911.73982.179639.669148.4234165.9679-138.6637QC'd by NCI-NPB
Inhibitor10Single point of activity00-3-30.74153.15832.3786-4.6143-4.83942.05472.0009-1.0351-6.02710.6182-19.358410.4489-30.7415QC'd by Analyticon
Inhibitor6.309658.840410Partial curve; partial efficacy; poor fit-5.20.60.417-65.9909-7.1505-2.40 0 0 0 0 0 0 0 0 0 0 1-28.9537-10.278-7.0923-12.3469-20.4971-17.6764-24.1328-4.8477-2.6254-57.8867-28.7749-43.6104-28.9537QC'd by Adooq
Inhibitor7.943335.709610Partial curve; partial efficacy; poor fit-5.11.62660.6292-32.20963.5-2.40 0 0 0 0 0 0 1 0 0 0 0-31.2215-8.6776-0.010226.2164.2017-7.6517-3.874711.94249.9824-11.8036-23.4099-21.0046-31.2215QC'd by MedChem Express
Inhibitor3548.1339245.146910Single point of activity-2.454.95490.8456-238.64696.5-30 0 0 0 0 0 0 0 0 0 0 0-189.2328-10.2316-11.668-5.7125-6.9939-6.83584.6961-0.7482-3.938510.139967.82411.1988-189.2328QC'd by SIGMA
Inhibitor3548.133962.154810Single point of activity-2.454.0950.6256-60.15482-30 0 0 0 0 0 0 0 0 0 0 0-44.97659.0235-3.711.40378.8489-20.5128-6.788510.687512.245816.8535-8.1934-5.3762-44.9765QC'd by Spectrum Chemical
Inhibitor3548.1339224.207110Single point of activity-2.454.95490.908-226.7071-2.5-30 0 0 0 0 0 0 0 0 0 0 0-188.92260.6552-3.0475-20.07884.3432-7.7208-4.391-10.9476-14.7305-15.72889.415518.4273-188.9226QC'd by Spectrum Chemical
Inactive0004-11.6855-10.3618-6.7493-13.8491-4.0803-8.693.1376-3.5124-6.64858.867923.3566-19.7661-11.6855QC'd by NIEHS
Inactive0-4.454.95490.59135.6731-7.278340 0 0 0 0 0 0 0 0 0 0 027.36422.8347-4.98130.3609-23.9819-6.2913-0.0932-3.8252-15.0975-15.0152-1.0423-10.058427.3642QC'd by NIEHS
Inactive0-5.251.3310.8583-16.27280.540 0 0 0 0 0 0 0 0 0 0 0-15.2273-2.78552.24051.2511-0.30423.2449-5.3421-1.1406-2.134-11.0911-10.1778-14.1452-15.2273QC'd by Microsource
Inactive0-74.95490.4875-12.02527.540 0 0 0 0 0 0 0 0 0 0 0-17.94165.45699.45630.9594-16.173-11.6471-23.6404-23.7713.0401-13.6573-3.3944-2.453-17.9416QC'd by SigmaAldrich
Inactive0-5.22.40640.526320.5918-9.057440 0 0 0 0 0 0 0 0 1 0 1-20.2572.5975-10.44924.0575-21.7145-4.1317-16.8048-9.6264-16.01219.3402-20.985518.4895-20.257QC'd by FLUKA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: DSHEA-v1-HepG2-viability-CTG-ATP
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; HepG2 cells, white solid-bottom tissue treated Greiner plate.
2; Incubation; 4 hrs; 37C, 95% humidity, 5% CO2.
3; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
4; Incubation; 24 hrs; 37C, 95% humidity, 5% CO2.
5; Reagent; 1 uL; GF-AFC substrate.
6; Incubation; 30 min; 37C, 95% humidity, 5% CO2.
7; Read 1; Fluorescence; EnVision plate reader excitation 380 nm, emission 510 nm.
8; Reagent; 3 uL; CellTiter-Glo (Promega).
9; Centrifuge; 1000 RPM; 15 seconds.
10; Incubation; 30 min; room temperature.
11; Read 2; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. 5 uL of HepG2 cells at 2 x 105 cells/mL (1,000 cells/well) were dispensed into a 1536-well white solid-bottom tissue treated plate (Greiner Bio-One) using a Multidrop Combi dispenser (Thermo Scientific). This assay use both GF-AFC substrate and Cell-Titer Glo (CTG), measuring cellular protease activity and ATP content, respectively.
2. Plates were incubated at 37C, 95% humidity, and 5% CO2 for ~4 hours to allow for cell attachment.
3. Compounds were transferred (16 nL) via pintool (Wako Automation), for a final concentration range for most substances of 15.6 nM - 31.3 uM.
4. Plates were incubated for ~24 hours.
5. 1 uL addition of GF-AFC substrate (final concentration 25 uM; MP Biomedicals).
6. Plates were incubated at 37C, 95% humidity, and 5% CO2 for 30 minutes.
7. After incubation, plates were read for fluorescence intensity (Ex/Em = 380 nm/510 nm) on an EnVision detector (PerkinElmer, Shelton, Connecticut).
8. Once the detection for fluorescence was completed, plates were dispensed with 3 uL of CellTiter-Glo (Promega, Madison, WI).
9. Plates were centrifuged for 15 seconds at 1,000 RPM's.
10. Plates were incubated for 30 minutes at room temperature.
11. Plates were then read for luminescence intensity on a ViewLux detector.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002650000 uMActivity at 0.0007960000 uMActivity at 0.00153 uMActivity at 0.00239 uMActivity at 0.00542 uMActivity at 0.00721 uMActivity at 0.020 uMActivity at 0.031 uMActivity at 0.065 uMActivity at 0.129 uMActivity at 0.211 uMActivity at 0.561 uMActivity at 1.029 uMActivity at 1.775 uMActivity at 3.419 uMActivity at 5.675 uMActivity at 15.05 uMActivity at 27.28 uMActivity at 46.63 uMActivity at 82.79 uMActivity at 166.3 uMActivity at 386.5 uMActivity at 772.9 uMActivity at 1548.0 uMActivity at 2788.1 uMActivity at 3130.0 uMCompound QC
Cytotoxic22.797961.23120Partial curve; partial efficacy-4.64212.33320.7712-61.2310-2.20 0 0 0 0 0 0 0 0 0 0 0-51.47355.6917-4.2609-4.661-0.3077-15.247-3.04449.4068-3.124918.1543-5.3424-18.3394-51.4735QC'd by NCI-NPB
Inconclusive12.820232.000210Partial curve; partial efficacy; poor fit-4.89214.44950.525634.51762.51742.40 0 0 0 0 0 0 0 0 0 0 034.70568.10847.3097-1.053914.4236-0.7015-16.235511.334319.7656-7.1794-4.717824.775334.7056QC'd by NCI-NPB
Inconclusive10Single point of activity00346.52646.695821.819313.13529.7751-1.53238.176711.666220.316911.67111.979229.782646.5264QC'd by NCI-NPB
Inactive00041.8115-8.61019.605515.434-0.3567-3.9177-3.00351.1368-5.155-4.9376-1.5358-0.54141.8115QC'd by NIEHS
Inactive00040.580310.3346-5.0785-2.29060.41275.5242-13.6160.0761-0.266-5.0674-0.5996-3.65180.5803QC'd by NIEHS
Inactive0-6.54.95490.3327-0.5-6.074540 0 0 0 0 0 0 0 0 0 0 0-2.0361-5.2982-6.3455-5.8012-5.3877-7.56213.7339.4322-5.5012-3.3336-1.6295-2.982-2.0361QC'd by Labotest
Inactive0004-0.7185-5.38794.5725-1.2462-11.4802-0.787-2.43139.1665-0.9492-2.7498-4.46670.2019-0.7185QC'd by Microsource
Inactive0004-4.2291-1.7188-2.6034-0.2713-4.3366-2.1957-0.8919-4.0357-7.55111.424-6.5558-4.9596-4.2291QC'd by SigmaAldrich
Inactive0-5.751.37230.58555-9.044840 0 0 0 0 0 0 0 0 0 0 04.4256-3.7216-4.6589-6.7245-21.704-9.1176-4.0994-3.3364-3.09522.5790.71536.90934.4256QC'd by FLUKA
Inactive0004-2.01241.20350.5793-1.822-2.87656.5877-1.6815-4.39618.28152.4849-5.9778-1.9907-2.0124QC'd by Timtec
Inactive0004-0.17617.223-5.78487.05355.0845-3.85426.8306-6.71680.1573-0.40320.0496-2.3582-0.1761QC'd by ASDI
Inactive0004-0.580.2902-3.5463-2.8261-6.415-1.5582-12.2023-8.7014-18.322811.5421-4.9283-8.8797-0.58QC'd by SigmaAldrich
Inactive0-6.253.92950.511110.5-3.181640 0 0 0 0 0 0 0 0 0 0 11.50267.9197-4.7433-10.9847-3.5133-1.875116.73078.503916.05412.344816.9534.27861.5026QC'd by SigmaAldrich
Inactive0-5.954.95490.35132-2.93440 0 0 0 0 0 0 0 0 0 0 01.2693-6.195-2.32442.1771-2.1126-5.6334-3.35488.7393-0.3622.4538-2.04282.23741.2693QC'd by Enamine
Inactive0-4.852.33320.41686.5-2.243640 0 0 0 0 0 0 0 0 0 0 03.56194.7584-5.769-1.50910.5565-8.953-2.7825-4.03920.6222-0.05660.44669.27173.5619QC'd by Enamine
Inactive0-5.653.1320.3135-1.26436.540 0 0 0 0 0 0 0 0 0 0 0-1.29713.4350.4106-2.92815.45538.601815.7725-1.11472.7804-4.80361.1426-1.5384-1.297QC'd by Enamine
Inactive0004-2.47981.951912.94890.71115.0049-5.09722.52630.9911.8038-3.6748-2.5487-1.4371-2.4798QC'd by SIGMA
Inactive00040.9216-0.5929-2.2871-8.73262.7556-14.4418-7.9159-4.3034-15.132415.326516.775-3.08830.9216QC'd by SIGMA
Inactive00044.52815.21052.726-14.4841-2.6953-2.635314.0351-6.9496-3.3776-2.5459-0.8869-3.07124.5281QC'd by LightBiologicals
Inactive0004-3.6012-9.5215-3.9752-3.8075-7.6401-1.83571.9718-7.5032-4.4669-4.3386-5.5746-6.6289-3.6012QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-agonist-ONEGlo
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive control rifampicin (RIF; final concentration range of 2.8 nM to 92uM for the agonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of the media in the agonist mode using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent agonists are ranked higher than compounds that showed apparent antagonists.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Activator14.3416104.68542Partial curve; high efficacy-4.843410.9919101.0889-3.59612.10 0 0 0 0 0 0 0 0 0 0 083.8217-5.0801-3.2987-3.4347-0.032-0.5082-3.4679-4.9059-2.01116.607233.435158.618783.8217QC'd by NCI-NPB
Activator25.5034117.202841Partial curve; high efficacy-4.59341.55790.972117.76270.55992.10 0 0 0 0 0 0 0 0 0 0 0103.3007-1.2511-2.7602-6.6167-0.0605-5.67752.2614-0.14648.643812.86419.114350.0412103.3007QC'd by NCI-NPB
Activator31.6228123.593440Partial curve; high efficacy-4.54.95490.9863122.5186-1.07482.10 0 0 0 0 0 0 0 0 0 0 0106.3529-1.8934-3.4581-3.7753-0.6018-3.758-4.229-0.9602-3.3997.09925.555816.7238106.3529QC'd by Analyticon
Activator28.183895.483440Partial curve; partial efficacy-4.551.96730.983596.32520.84182.20 0 0 0 0 0 0 0 0 0 0 072.9863-0.90180.35540.70880.1280.3466-1.38184.17771.71428.226217.96232.910672.9863QC'd by MedChem Express
Activator31.6228133.31840Partial curve; high efficacy-4.51.92820.9932132.865-0.4532.10 0 0 0 0 0 0 0 0 0 0 1-26.5067-1.345-2.46089.2529-0.3764-2.2195-0.666.200620.341762.313997.1543124.4054-26.5067QC'd by USP
Activator1.139282.369826Complete curve; partial efficacy-5.94344.95490.980679.5801-2.78971.20 0 0 0 0 0 0 0 0 0 0 1-8.8595-6.0747-3.93610.8373-3.8801-4.3545-1.7272-0.513610.874178.708390.844968.7426-8.8595QC'd by NCI-NPB
Activator2.27349.889423Complete curve; partial efficacy-5.64341.24750.958544.0109-5.87851.20 0 0 0 0 0 0 0 0 0 0 035.6087-4.4347-7.1334-8.2321-4.2161-5.6276-4.0085-4.3417.381919.996732.016651.531635.6087QC'd by NCI-NPB
Activator4.535247.623422Complete curve; partial efficacy-5.343410.97538.4365-9.18691.20 0 0 0 0 0 0 0 0 0 0 032.3303-6.888-9.4868-10.9846-13.4891-7.3468-8.7296-2.7383-1.26776.575419.047135.092932.3303QC'd by NCI-NPB
Activator16.091648.572421Partial curve; partial efficacy-4.79341.62590.96747.6766-0.89582.20 0 0 0 0 0 0 0 0 0 0 043.41312.86553.37681.2511-0.5359-5.7465-5.372-1.002-0.61711.29410.870830.007143.4131QC'd by NCI-NPB
Activator7.079533.998521Complete curve; partial efficacy-5.151.62660.860433.027-0.97141.20 0 0 0 0 0 0 0 0 0 0 036.6967-1.92390.55984.07911.538-1.549-1.5547-4.55952.667717.157325.347717.240236.6967QC'd by Microsource
Activator14.125445.012521Complete curve; partial efficacy-4.852.33320.950549.01133.99891.20 0 0 0 0 0 0 0 0 0 0 043.90152.575410.42212.13222.62136.6166-9.0E-46.93954.058112.340318.178742.030143.9015QC'd by MedChem Express
Activator11.220240.232521Partial curve; partial efficacy-4.951.41630.934335-5.23252.20 0 0 0 0 0 0 0 0 0 0 033.2046-4.1192-4.572-4.0695-3.3798-5.8283-3.6991-3.6725-6.44379.890318.689517.954533.2046QC'd by Analyticon
Activator14.125458.328721Complete curve; partial efficacy-4.852.53340.979458.89750.56881.20 0 0 0 0 0 0 0 0 0 0 054.63993.51161.77872.62132.4685-2.9488-3.0533-4.10945.3066.893821.233747.459654.6399QC'd by Bio Vision
Activator1040.410521Complete curve; partial efficacy-51.92820.993234.9051-5.50541.20 0 0 0 0 0 0 0 0 0 0 033.2856-5.0152-7.9212-4.8471-4.7554-6.2842-4.5937-3.4997-2.62783.878519.443327.128633.2856QC'd by DC Chemicals
Activator125.892542.598721Partial curve; partial efficacy-3.93.51170.976137.4259-5.17282.20 0 0 0 0 0 0 0 0 0 0 035.6074-5.598-4.4535-4.6006-3.7313-6.9471-4.1018-8.894-6.2272-3.9162-0.216711.113435.6074QC'd by VWR
Activator89.125161.805321Partial curve; partial efficacy-4.052.25260.958363.8512.04572.20 0 0 0 0 0 0 0 0 0 0 056.34353.54612.34033.8269-0.5044-2.87860.16810.48344.07334.340220.973641.969856.3435QC'd by USP
Activator44.668433.361120Partial curve; partial efficacy-4.354.95490.928130.4844-2.87672.20 0 0 0 0 0 0 0 0 0 0 033.48350.7298-3.8211-2.4723-0.4853-2.48731.9269-1.5566-7.3972-6.9654-4.191314.437833.4835QC'd by SIGMA
Activator28.183859.492320Partial curve; partial efficacy-4.552.12110.981559.2264-0.26592.20 0 0 0 0 0 0 0 0 0 0 045.1170.14330.4757-1.1368-1.91440.9583-2.3049-1.3742-0.09592.436810.915519.43245.117QC'd by Specs
Activator22.387250.321220Partial curve; partial efficacy-4.652.33320.967848.961-1.36022.20 0 0 0 0 0 0 0 0 0 0 041.6305-1.0546-0.51781.05653.204-3.1958-2.6962-3.3382-2.3942-3.633510.231422.986341.6305QC'd by NIEHS
Activator22.387266.762120Partial curve; partial efficacy-4.652.04790.966765.0924-1.66972.20 0 0 0 0 0 0 0 0 0 0 053.3263-3.567-2.19723.9071-0.7451-1.2565-1.6762-4.72480.0598-4.496616.107630.04653.3263QC'd by NIEHS
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-agonist-CTF
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9muM), positive control rifampicin (RIF; final concentration range of 2.8 nM to 92muM for the agonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92muM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1muL of the media in the agonist mode using a BioRAPTR FRD and incubated for approximately 24 h at 37 degrees C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for 1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent agonists are ranked higher than compounds that showed apparent antagonist.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Activator10Single point of activity00341.251116.813917.13085.80418.210214.6289.27613.99792.179316.701126.08719.50741.2511QC'd by Axon Medchem
Inhibitor25.118979.49940Partial curve; partial efficacy-4.61.88510.8809-80.4994-1-2.20 0 0 0 0 0 0 0 0 0 0 0-60.9844-8.3599-4.1108-0.3444-11.57673.51984.96689.57164.2331-17.2158-11.7715-39.1274-60.9844QC'd by Timtec
Inhibitor31.622895.56340Partial curve; partial efficacy-4.52.35310.8631-96.0634-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0-72.7753-6.8881-3.3208-3.076112.75391.9093-0.79046.82312.6146-7.9331-23.5282-18.0196-72.7753QC'd by Timtec
Inactive00043.91194.76885.58121.6514-8.3499.23334.32514.0356-0.3615-0.20432.6808-0.05673.9119QC'd by NIEHS
Inactive000418.652220.020718.124212.823317.177811.506418.62087.82268.595319.387611.249215.190218.6522QC'd by NIEHS
Inactive0004-11.0235-2.3288-4.9883-2.058-0.38911.1259-8.97082.0241-9.4201-17.1740.791-14.7061-11.0235QC'd by Labotest
Inactive000414.94214.331612.073613.839416.423416.703618.466110.421912.281514.093932.403514.704114.942QC'd by Microsource
Inactive0-4.81.34370.7327-16.04564.540 0 0 0 0 0 0 0 0 0 0 0-11.70460.8383.85191.95357.87343.649512.16163.08212.972-4.30770.1241-9.682-11.7046QC'd by SigmaAldrich
Inactive0-4.653.51170.4081-2.772715.540 0 0 0 0 0 0 0 0 0 0 0-0.643924.925419.07386.06058.42513.415214.919313.794910.669128.759616.52654.2985-0.6439QC'd by FLUKA
Inactive00049.865315.383915.794915.578215.8417.366323.775316.400716.948131.430234.187610.08299.8653QC'd by Timtec
Inactive0-5.44.95490.750319.50.154240 0 0 0 0 0 0 0 0 0 0 016.28962.35072.13075.21067.939-2.1412-1.3331-10.70490.36123.079919.405916.9116.2896QC'd by ASDI
Inactive00046.82660.56726.1190.08513.771-5.7981.34010.590111.032-3.46779.52992.45976.8266QC'd by SigmaAldrich
Inhibitor79.432851.08290Single point of activity-4.13.1320.677-54.5829-3.5-30 0 0 0 0 0 0 0 0 0 0 0-41.3507-6.1955-5.5479-3.6187-6.2729-3.8883-5.9198-10.8577-7.72274.9878-3.69855.5592-41.3507QC'd by SigmaAldrich
Inactive0-4.650.40.5286-34.1016-11.466340 0 0 0 0 0 0 0 0 0 0 0-26.6686-12.5178-8.3053-23.8027-16.0657-16.4067-11.8517-17.1711-20.3545-24.4433-18.1564-26.7513-26.6686QC'd by Enamine
Inactive0-5.34.95490.8647-29.0962-15.214140 0 0 0 0 0 0 0 0 0 0 1-21.5077-17.6173-18.2501-11.8451-14.8537-13.8162-13.1838-16.9815-24.3417-32.9968-29.0139-25.1086-21.5077QC'd by Enamine
Inactive0-5.14.95490.34640-5.205440 0 0 0 0 0 0 0 0 0 0 02.58220.981-6.223-5.7422-5.1579-4.8896-3.0017-9.3378-8.03122.34741.1285-5.59092.5822QC'd by Enamine
Inactive0-60.40.35621.5-11.481840 0 0 0 0 0 0 0 0 0 0 00.1828-6.6154-8.3148-15.81811.639-3.4473-7.9188-3.2712-2.5357-4.00081.1316-1.94090.1828QC'd by SIGMA
Inactive0-4.354.95490.7563-8.091740 0 0 0 0 0 0 0 0 0 0 02.7625-9.96-6.5741-10.0388-9.5144-5.5606-4.3237-10.9098-6.7845-8.0245-8.0118-1.73312.7625QC'd by SIGMA
Inactive0-50.50.61918-18.187840 0 0 0 0 0 0 0 0 0 0 1-16.5209-21.4065-10.9296-12.17-15.9227-14.8775-9.3127-3.8321-10.7718-11.73733.6244-0.1854-16.5209QC'd by LightBiologicals
Inactive0-5.350.40.5288-28.3571-8.718440 0 0 0 0 0 0 0 0 0 0 0-24.4642-11.2992-10.283-18.738-15.1055-5.5987-16.1145-24.2525-18.6306-20.4752-19.2793-22.796-24.4642QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA polymerase kappa [Homo sapiens]
External ID: PolK100
Protocol: Three microliters of reagents (buffer in column 3 and 4 as negative control and 10 nM Pol kappa in columns 1, 2, and 5-48) were dispensed into a 1536-well black solid-bottom plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array. The plates were then incubated for 15 min at room temperature, and 1 uL substrate (50 nM final concentration) were then added to start the reaction and kinetically read twice at 0 min and 10 min on the Viewlux reader
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003270000 uMActivity at 0.0007732774 uMActivity at 0.00163 uMActivity at 0.00369 uMActivity at 0.00818 uMActivity at 0.020 uMActivity at 0.030 uMActivity at 0.047 uMActivity at 0.101 uMActivity at 0.151 uMActivity at 0.243 uMActivity at 0.477 uMActivity at 0.759 uMActivity at 1.287 uMActivity at 2.393 uMActivity at 3.818 uMActivity at 6.336 uMActivity at 11.99 uMActivity at 19.37 uMActivity at 31.37 uMActivity at 60.11 uMActivity at 107.2 uMActivity at 158.4 uMActivity at 229.0 uMCompound QC
Inactive40 0 0 0 01.4694-3.5669-6.2352.85861.80421.4694QC'd by "Chem Div"
Inactive40 0 0 0 0-4.26318.22188.081110.2927-3.9947-4.2631QC'd by "Chem Div"
Inactive40 0 0 0 06.03690.3398-2.1048-8.1695-3.68226.0369QC'd by "Chem Div"
Inactive4-2.05651.7294-3.5894-1.2575-0.5402-2.0565QC'd by "Chem Div"
Inactive40 0 0 0 12.31491.00484.6369-1.9963-3.35432.3149QC'd by "Chem Div"
Inactive47.27487.15156.13721.51975.23327.2748QC'd by "Chem Div"
Inactive40 0 0 0 01.006-3.3873-7.786-9.3037-9.17611.006QC'd by "Chem Div"
Inactive40 0 0 0 0-0.0368-9.4458-10.5155-9.0065-12.9141-0.0368QC'd by "Chem Div"
Inactive40 0 0 0 02.6-7.8084-12.3007-2.0954-6.68872.6QC'd by "Chem Div"
Inactive40 0 0 0 0-11.4867-18.9051-17.4955-19.0735-9.6682-11.4867QC'd by "Chem Div"
Inactive40 0 0 0 0-7.5605-17.2173-11.0038-16.5656-22.4025-7.5605QC'd by "Chem Div"
Inactive4-7.5451-1.1939-1.3084-5.8268-5.3206-7.5451QC'd by "Chem Div"
Inactive40 0 0 0 1-5.5852-4.3753-1.0046-3.1641-10.1524-5.5852QC'd by "Chem Div"
Inactive40 0 0 0 01.1172-6.03917.01189.04461.65331.1172QC'd by "Chem Div"
Inactive42.33591.25181.6626-0.9325-0.91942.3359QC'd by "Chem Div"
Inactive40 0 0 0-19.53540.3984-4.11472.1883-19.5354QC'd by "Chem Div"
Inactive4-5.6552-4.6769-1.9378-0.5867-3.224-5.6552QC'd by "Chem Div"
Inactive4-11.3738-10.4148-13.8912-10.4252-7.8961-11.3738QC'd by "Chem Div"
Inactive4-6.1571-8.7102-2.9113-5.2229-3.4369-6.1571QC'd by "Chem Div"
Inactive40 0 0 0 1-7.3803-8.8177-11.1654-6.5301-15.9483-7.3803QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:SRMLSC 靶标:N/A
External ID: BCAT SD DP Set
Protocol: Cell Culture: HCT116 cells lacking activated Beta Catenin were subcultured every 3-4 days in McCoy's 5A medium with 10% fetal bovine serum, 100 U/mL penicillin, 100 ug/mL streptomycin and 2 mM glutamine (complete growth medium), incubated at 37 degrees C in 5% carbon dioxide, and maintained at sub-confluent density for no more than 20 passages.

Compound Dosing/Plating: Carrier or sulindac sulfide (Sigma-Aldrich) were diluted in complete growth medium to prepare a 3X concentrated dosing solution (300 uM sulindac sulfide /0.3% DMSO) which was dispensed into 96-well black clear-bottom tissue culture treated plates (50 uL volume). This resulted in a final culture volume in assay plates of 150 uL, with final concentrations of 100 uM sulindac sulfide (0.1% DMSO) for the controls and 10 uM (0.1% DMSO) for the library compounds.

Cell Plating: One hundred uL of complete growth medium containing 5,000 cells were dispensed per well, while stirring. Plates were incubated at room temperature for 30 min prior to incubation at 37 degrees C in 5% carbon dioxide for 60 h.

Endpoint/Detection: At the end of the treatment period, assay plates were removed from the incubator and equilibrated to room temperature 10 min. One hundred uL of Cell Titer Glo reagent was added and plates were incubated for an additional 10 min in the dark. At the end of the incubation, assay plates were analyzed using a PerkinElmer Victor3V microplate reader with an integration time of 1.0 s in luminescence mode.
Comment: Possible artifacts in this assay include, but are not limited to, compounds that interfere with the luciferase reaction, absorb luminescence, or precipitate.

Outcome:
The effect of library compounds at 10 uM on viability of HCT116 cells expressing activated Beta Catenin was calculated as follows:

% Viability = 100*(Cmpd Lum) /(Median Cell Ctrl Lum )
Compounds that reduced viability to <= 29.74% were scored as active (the median viability value for all experimental compounds [96.32%] minus 3 times the standard deviation [22.19%]).

Based on a 3-tiered scoring system, primary screening data received a score from 0 to 40 as an inverse function of % viability, where 100% viability or higher corresponds to a score of 0 and 0% viability corresponds to a score of 40.
Viability
79.46
88.83
99.51
98.6
86.07
98.91
100.63
91.95
97.07
98.69
95.95
106.56
96.28
100.97
44.63
95.5
96.44
49.09
98.34
100.3
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: DSHEA-v1-KB-8-5-11-CTG
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; KB-8-5-11 cells, white solid-bottom tissue treated Greiner plate.
2; Incubation; 4 hrs; 37C, 95% humidity, 5% CO2.
3; Compounds and control; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
4; Incubation; 72 hrs; 37C, 95% humidity, 5% CO2.
5; Reagent; 2.5 uL; CellTiter-Glo.
6; Centrifuge; 1000 RPM; 15 seconds.
7; Incubation; 30 min; room temperature.
8; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. P-gp-overexpressing subline KB-8-5-11 were maintained in DMEM (Thermofisher catalog #11965) with 10% FBS and 1% penicillin/streptomycin at 37C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/ml (after initial cell attachment). For the screen, assay medium was identical to culture medium except for KB-8-5-11, where colchicine was excluded from the medium. Briefly, 5 uL of cells at 1 x 105 cells/mL (500 cells/well) were dispensed into a 1536-well white solid-bottom tissue treated plate (Greiner Bio-One) using a Multidrop Combi dispenser.
2. Plates were incubated at 37C, 95% humidity, 5% CO2 for ~4 hours to allow for cell attachment.
3. Compounds and intraplate control (Bortezomib; final concentration range 228 pM - 7.5 uM) were transferred (16 nL) via pintool (Wako Automation), for a final concentration of 15.6 nM - 30.0 uM (most substances).
4. Plates were incubated for ~72 hours at 37C, 95% humidity, 5% CO2.
5. Plates were then dispensed with 2.5 uL of CellTiter-Glo.
6. The assay plates were centrifuged for 15 seconds at 1,000 RPM's.
7. The plates were incubated for 30-minute at room temperature.
8. Luminescence intensity was detected using a PerkinElmer ViewLux microplate reader.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds (inhibition of viability) are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
3. In addition, activity in the P-gp counter screens is defined as a sample yielding a CRC of -1.1, -1.2, -2.1, or -2.2 in the KB-3-1 assay and selective (or potentially interacting with P-gp) if it has an IC50 ratio of >5 vs KB-8-5-11 (if activity was observed).
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002540000 uMActivity at 0.0007610000 uMActivity at 0.00146 uMActivity at 0.00228 uMActivity at 0.00518 uMActivity at 0.00689 uMActivity at 0.019 uMActivity at 0.030 uMActivity at 0.062 uMActivity at 0.124 uMActivity at 0.201 uMActivity at 0.536 uMActivity at 0.983 uMActivity at 1.693 uMActivity at 3.263 uMActivity at 5.424 uMActivity at 14.38 uMActivity at 26.09 uMActivity at 44.54 uMActivity at 79.09 uMActivity at 158.8 uMActivity at 368.8 uMActivity at 738.4 uMActivity at 1478.8 uMActivity at 2661.4 uMActivity at 2990.0 uMCompound QC
Inhibitor30.6056107.491440Partial curve; high efficacy-4.51423.62720.9591-111.4914-4-2.10 0 0 0 0 0 0 0 0 0 0 0-90.2034-4.12330.8968-1.5418-5.7798-4.47411.03050.9939-0.6949-11.3538-15.9328-11.263-90.2034QC'd by NCI-NPB
Inhibitor22.387241.518910Partial curve; partial efficacy; poor fit-4.653.06540.836-35.01896.5-2.40 0 0 0 0 0 0 0 0 0 0 0-25.84916.97333.63664.50590.86967.01266.20727.45880.762712.511411.13830.8201-25.8491QC'd by Axon Medchem
Inhibitor34.3449.816510Single point of activity-4.46424.44950.9573-52.8165-3-30 0 0 1 0 0 0 1 0 0 0 0-41.1488-4.30581.5332-1.85-38.4337-5.3086-4.2671-5.293-50.2745-6.31020.0801-3.0113-41.1488QC'd by NCI-NPB
Inhibitor34.3458.695610Single point of activity-4.46424.95490.8872-65.6631-6.9675-30 0 0 0 0 0 0 1 0 0 0 0-53.304-5.6351-6.8069-3.3063-21.065-7.6092-5.2301-3.6022-43.8707-6.1139-6.5504-3.6926-53.304QC'd by NCI-NPB
Inhibitor27.277245.259610Single point of activity-4.56424.44950.8339-45.25960-30 0 0 0 0 0 0 0 0 0 0 0-40.8234-5.78850.42842.6213-5.2884-0.44925.49082.2288-7.0576-2.849911.8917-2.8101-40.8234QC'd by NCI-NPB
Inhibitor25.118934.585610Partial curve; partial efficacy; poor fit-4.63.51170.799-36.5856-2-2.40 0 0 0 0 0 0 0 0 0 0 0-27.1546-4.87-1.90560.6614-5.9249-2.23940.3421-3.04-6.4069-3.40662.9859-0.914-27.1546QC'd by Analyticon
Inhibitor22.387260.027810Single point of activity-4.652.40640.8749-59.52780.5-30 0 0 0 0 0 0 0 0 0 0 0-45.09680.1178-1.92032.8406-3.02690.77274.11891.8876-6.9261-5.78262.4323-8.6388-45.0968QC'd by Bio Vision
Inhibitor25.118957.805110Single point of activity-4.64.95490.7368-54.80513-30 0 0 0 0 0 0 0 0 0 0 0-40.9462-2.3376-2.17327.84344.0118-1.5862-1.2057-4.0442-1.939515.754.255213.6882-40.9462QC'd by MedChem Express
Inhibitor2511.886496.128210Single point of activity-2.64.44950.8441-94.12822-30 0 0 0 0 0 0 0 0 0 0 0-71.30920.603913.20852.3786-7.8588-8.17725.0709-0.5163-4.6021-1.30115.44812.385-71.3092QC'd by SIGMA
Inhibitor2511.8864100.067810Single point of activity-2.63.06540.912-101.0678-1-30 0 0 0 0 0 0 0 0 0 0 0-76.5665-0.4138-1.84530.7759-5.4714-6.6638-3.28060.2434-3.7431-4.03018.6175-8.758-76.5665QC'd by Spectrum Chemical
Inactive0004-3.8119-7.2253.8053-1.8663-2.1729-4.1366-2.017-1.8291-4.1373-3.7318-3.2428-1.7799-3.8119QC'd by NIEHS
Inactive00046.15843.5626.85334.14472.4419-4.945-2.42164.80122.3613-3.41891.1698.02936.1584QC'd by NIEHS
Inactive0-5.152.78680.870310.5-4.814840 0 0 0 0 0 0 0 0 0 0 11.4272-4.2961-3.5021-4.3626-5.5817-6.887-0.6904-6.929-4.8929-2.40823.18698.70381.4272QC'd by Labotest
Inactive0-5.54.95490.685211.50.075440 0 0 0 0 0 0 0 0 0 0 07.29850.80383.54130.3334-5.7705-3.2926.55791.0015-0.91387.714613.271613.35447.2985QC'd by Microsource
Inactive0-5.251.71370.952118-2.492740 0 0 0 0 0 0 0 0 0 0 015.7077-1.5376-4.2349-2.7016-4.5773-1.3499-3.67941.11841.60822.396610.492816.917815.7077QC'd by SigmaAldrich
Inactive0-4.754.95490.4692-8.37675.540 0 0 0 0 0 0 0 0 0 0 0-8.64733.29225.49294.395-0.7619.906112.2286.1368-3.00738.980310.24160.8488-8.6473QC'd by FLUKA
Inactive0-5.454.95490.60788-1.80140 0 0 0 0 0 0 0 0 0 0 06.6155-7.3342-2.02410.2845.6963-4.8439-0.28561.0332-6.20394.81457.61939.91426.6155QC'd by Timtec
Inactive0004-2.5671-0.58691.81771.477-1.2963-1.5289-1.12924.2607-3.9676-3.00885.54250.0253-2.5671QC'd by ASDI
Inactive0-4.950.90.7682211.351940 0 0 0 0 0 0 0 0 0 0 015.9482-1.79010.32925.29431.0981-1.16436.61896.35033.83083.06419.557512.801415.9482QC'd by SigmaAldrich
Inactive0-5.354.0950.48693.5-3.803840 0 0 0 0 0 0 0 0 0 0 06.2131-0.3639-8.06250.9742-8.5865-2.3741-0.3118-6.8623-0.26750.94466.305-0.10116.2131QC'd by Enamine
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-cyp1a2
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; cytochrome P450 enzyme and luciferin substrate or buffer only, white solid-bottom Greiner plate.
2; Compounds and control; 16 nL; Kalypsis pintool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 15 min; room temperature.
4; Reagent; 2 uL; nicotinamide adenine dinucleotide phosphate (NADPH).
5; Incubation; 30 - 45 min; room temperature in the dark.
6; Reagent; 4 uL; P450-Glo assay detection reagent.
7; Centrifuge; 1000 RPM; 15 seconds.
8; Incubation; 30 min; room temperature.
9; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. A 2 uL mixture of corresponding enzymes and luciferin substrate (final concentrations CYP enzyme-specific and pro-luciferin substrate-specific) or minus-enzyme (assay buffer conditions supplied by the manufacturer for respective enzyme isoform; typically, 100 mM KPO4) and luciferin substrate were dispensed using a BioRAPTR FRD (Beckman Coulter, Brea, CA) into columns of a 1536-well white solid-bottom medium binding plate (Greiner Bio-One, Monroe, NC). Five isoforms of cytochrome P450 were used (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).
2. Substances (final concentrations of most substances ranged from 19.5 nM to 39.8 uM) and controls (CYP-specific) were transferred (16 nL) via pintool (Wako Automation, Richmond, VA). Intraplate controls furafylline (CYP1A2), sulfaphenazole (CYP2C9), ketoconazole (CYP2C19), quinidine (CYP2D6), and ketoconazole (CYP3A4) were used correspondingly.
3. Assay plates were incubated at room temperature for 15 min.
4-5. Two uL of reduced nicotinamide adenine dinucleotide phosphate (NADPH) regeneration solution (final concentration 1x) was dispensed to initiate the reaction, which then proceeded for 30-45 min (RT, protected from light), allowing NADP+ to convert to NADPH, which then serves as the electron source for the CYP oxidative reactions leading to the pro-luciferin substrate to convert to D-luciferin.
6-8. Next, 4 uL of reconstituted luciferin detection reagent was dispensed to allow for D-luciferin to be converted to light via luciferase reaction. Samples were centrifuged for 15 s at 1000 rpm (233 g) to remove bubbles, followed by an RT incubation for 30 min.
9. Plates were then read for luminescence intensity on a ViewLux detector (PerkinElmer; Waltham, MA).

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003590000 uMActivity at 0.00108 uMActivity at 0.00207 uMActivity at 0.00323 uMActivity at 0.00733 uMActivity at 0.00975 uMActivity at 0.027 uMActivity at 0.042 uMActivity at 0.087 uMActivity at 0.175 uMActivity at 0.285 uMActivity at 0.759 uMActivity at 1.389 uMActivity at 2.398 uMActivity at 4.622 uMActivity at 7.675 uMActivity at 20.33 uMActivity at 36.98 uMActivity at 63.09 uMActivity at 111.8 uMActivity at 224.7 uMActivity at 522.5 uMActivity at 1045.0 uMActivity at 2089.9 uMActivity at 3764.0 uMActivity at 4240.0 uMCompound QC
Inactive0-5.44.95490.913520.5-1.220840 0 0 0 0 0 0 0 0 0 0 022.39131.21821.55412.57243.105-5.6006-4.3175-3.4912-1.795617.044917.545820.469122.3913QC'd by Specs
Inactive0-5.54.95490.856733.587440 0 0 0 0 0 0 0 0 0 0 027.75464.09640.82961.34131.837310.11537.837210.23359.199843.313735.44527.424227.7546QC'd by Microsource
Inactive0-5.44.95490.883715.5-2.993140 0 0 0 0 0 0 0 0 0 0 017.51741.0007-0.8293-1.2265-0.165-4.0194-5.5455-8.3275-4.253815.389114.622412.134617.5174QC'd by Microsource
Inactive0-4.653.1320.9976-33.0955840 0 0 0-27.57967.61024.9164-11.9202-27.5796QC'd by Microsource
Inactive0-5.44.95490.917-20.4511-1.581740 0 0 0 0 0 0 0 0 0 0 0-21.2215-1.667-0.068-1.3678-1.1479-3.0073-3.7658-1.9839-1.6245-18.6106-24.9593-14.3322-21.2215QC'd by Prestwick
Inactive0-4.454.95490.6301-11.32620.540 0 0 0 0 0 0 0 0 0 0 0-7.7718-0.80480.31610.3582.6747-0.58480.21461.80663.2856-2.1391-2.73796.0E-4-7.7718QC'd by Microsource
Inactive0004-4.8234.18015.07911.8382-4.823QC'd by Microsource
Inactive00043.10542.89791.61010.85893.1054QC'd by Microsource
Inactive0-5.254.95490.5092-3.8291.540 0 0 0 0 0 0 0 0 0 0 0-1.30343.6585-0.9451-1.2745-0.35635.50641.34992.16633.6365-0.1732-6.9408-3.0684-1.3034QC'd by MedChem Express
Inactive0-5.454.95490.913616.50.714540 0 0 0 0 0 0 0 0 0 0 012.65262.72043.30240.8205-2.32120.00671.1980.32020.559717.521418.092216.144712.6526QC'd by SIGMA
Inactive0-5.44.95490.763-16.1876040 0 0 0 0 0 0 0 0 0 0 0-16.0687-2.3403-3.464-3.2312-3.51672.19994.81610.12884.4256-16.7414-9.2039-20.9897-16.0687QC'd by Microsource
Inactive0-4.653.51170.9822-9.65356.540 0 0 0-7.62795.81786.6201-1.4316-7.6279QC'd by Analyticon
Inactive0-4.851.69240.8705-22.3507340 0 0 0 0 0 0 0 0 0 0 0-20.70891.0054-0.13981.4478-0.31047.825.4745.45183.6927-3.2246-8.3225-10.2741-20.7089QC'd by Microsource
Inactive0-5.454.95490.8717-2.116140 0 0 0 0 0 0 0 0 0 0 010.86120.50762.58221.0644-4.0539-4.6801-2.9883-2.6436-3.061118.105119.443518.215910.8612QC'd by Microsource
Inactive0-5.54.95490.864513.54.540 0 0 0 0 0 0 0 0 0 0 16.68222.67465.90553.68324.62713.76644.4935.90696.243615.115914.436810.27096.6822QC'd by Microsource
Inactive0-5.44.95490.69518-4.370840 0 0 0 0 0 0 0 0 0 0 1-1.3133-0.0083-0.6265-1.819-2.0562-6.8959-9.059-7.3098-6.7669.87966.37526.0433-1.3133QC'd by Analyticon
Inactive0-5.454.95490.4962-5.733-0.540 0 0 0 0 0 0 0 0 0 0 1-0.1118-0.586-3.5626-1.6504-1.92640.3771-0.66822.99090.8097-8.1108-7.6014-2.0255-0.1118QC'd by Microsource
Inactive0-5.14.95490.7037.5-4.172540 0 0 0 0 0 0 0 0 0 0 04.1113-0.7963-0.8961-0.213-0.0542-7.3034-8.0604-7.0814-7.55048.60377.49469.41514.1113QC'd by Analyticon
Inactive0-5.44.95490.907621.5-0.97740 0 0 0 0 0 0 0 0 0 0 021.09793.66511.30641.22730.1534-2.5135-4.9808-3.8686-3.153523.167519.45820.075321.0979QC'd by Microsource
Inactive0-5.551.10.7624222.540 0 0 0 0 0 0 0 0 0 0 016.68121.58723.70712.22721.33967.20578.89446.03064.573621.870122.869117.979216.6812QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: DSHEA-v1-counterscreen-LDR
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 4 uL; D-luciferin or buffer only, white solid-bottom Greiner plate.
2; Compounds and control; 16 nL; Kalypsis pintool (Wako USA).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; luciferin detection reagent.
5; Centrifuge; 1000 RPM; 15 sec.
6; Incubation; 30 min; room temperature.
7; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. To account for detection kit artifacts, compounds were counter-screened for interferences using previously described methods [2]. Briefly, 4 uL of D-luciferin (final concentration 1 uM) or buffer (100 mM potassium phosphate) were dispensed into a 1536-well white solid-bottom medium binding plate.
2-3. Compounds (final concentration of 19.5 nM to 39.8 uM) and intraplate control PTC124 (final concentration range: 1.2 nM to 39.8 uM) were transferred (16 nL) via pintool (Wako Automation) and incubated (RT) for 15 min.
4-6. Next, 4 uL of reconstituted luciferin detection reagent was dispensed, and samples were centrifuged for 15 s at 1000 rpm and incubated (RT) for 30 min.
7. Plates were then read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Auld DS, Southall NT, Jadhav A, Johnson RL, Diller DJ, Simeonov A, Austin CP, Inglese J. Characterization of chemical libraries for luciferase inhibitory activity. J Med Chem. 2008 Apr 24;51(8):2372-86. doi: 10.1021/jm701302v. Epub 2008 Mar 26. PMID: 18363348.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003320000 uMActivity at 0.0009960000 uMActivity at 0.00191 uMActivity at 0.00299 uMActivity at 0.00678 uMActivity at 0.00903 uMActivity at 0.025 uMActivity at 0.039 uMActivity at 0.081 uMActivity at 0.162 uMActivity at 0.263 uMActivity at 0.702 uMActivity at 1.291 uMActivity at 2.222 uMActivity at 4.274 uMActivity at 7.106 uMActivity at 18.80 uMActivity at 34.14 uMActivity at 58.33 uMActivity at 103.6 uMActivity at 207.7 uMActivity at 483.1 uMActivity at 966.3 uMActivity at 1932.0 uMActivity at 3487.5 uMActivity at 3920.0 uMCompound QC
Inactive0004-1.8663-2.3259-0.0777-0.8772-2.3066-2.3294-2.7733-2.0491-2.5071-1.315-1.9192-1.2021-1.8663QC'd by Timtec
Inactive0004-2.0819-1.8369-1.6849-0.3832-1.686-3.8473-3.1973-3.1217-3.8317-3.178-1.3605-1.3912-2.0819QC'd by NIEHS
Inactive0004-3.8727-2.7709-2.9584-2.2437-2.8928-5.0152-5.3273-3.1516-3.9021-4.1654-4.7196-3.2933-3.8727QC'd by NIEHS
Inactive00041.86284.3487-2.6855.13185.53731.25442.1691.10822.00960.55452.04571.46541.8628QC'd by Labotest
Inactive0004-3.347-1.0109-0.4487-1.3718-0.308-2.0346-4.6346-2.9602-5.0981-0.592-3.704-1.2405-3.347QC'd by Microsource
Inactive0004-0.82133.8495.27166.43325.20910.0149-0.43990.2345-0.5540.0495-0.78130.1222-0.8213QC'd by SigmaAldrich
Inactive0004-0.88262.43632.01321.17961.1239-0.4381-0.9011-1.0946-1.32831.52691.1548-0.3505-0.8826QC'd by FLUKA
Inactive0004-3.4854-1.1109-2.6768-0.5276-1.9941-4.343-6.0476-3.4362-4.8783-2.8988-4.3105-2.5318-3.4854QC'd by Timtec
Inactive0004-2.8657-2.453-1.5388-1.7053-1.9475-4.7608-3.1142-3.9281-2.1606-4.8375-3.4941-3.9099-2.8657QC'd by ASDI
Inactive0004-1.56-6.619-8.7013-6.6386-8.5167-2.4768-4.0906-2.1866-3.8675-1.2075-2.427-0.1879-1.56QC'd by SigmaAldrich
Inactive0004-0.6844-0.8139-0.567-1.7074-0.68691.31681.97622.09443.39541.20650.95590.5189-0.6844QC'd by SigmaAldrich
Inactive0004-0.62161.94024.07284.00453.8847-4.8461-1.2233-0.6254-0.8611-3.1218-0.7666-1.0075-0.6216QC'd by Enamine
Inactive0-6.151.62660.6691-3.4924340 0 0 0 0 0 0 0 0 0 0 0-1.63542.25562.51393.12743.7853-2.093-1.2526-2.0142-1.4981-2.6538-8.327-2.9164-1.6354QC'd by Enamine
Inactive0004-3.3611-2.8978-3.8133-5.1211-4.1404-0.3089-1.5003-2.6968-1.6576-0.84380.009-2.9867-3.3611QC'd by Enamine
Inactive0004-1.0261-4.1716-4.3628-3.5652-3.4256-1.2325-1.7293-0.5907-1.0043-2.4661-2.8361-1.7658-1.0261QC'd by SIGMA
Inactive00043.54020.02490.52151.60071.8451.07672.35991.59341.93652.61312.95943.8773.5402QC'd by SIGMA
Inactive00040.51-0.7844-0.0901-1.9608-1.3490.78060.7197-0.24120.60991.92971.61660.02070.51QC'd by LightBiologicals
Inactive0-6.44.95490.8207-3.463.540 0 0 0 0 0 0 0 0 0 0 0-3.60582.72241.87364.84162.1811-3.1921-4.0726-1.2633-3.446-6.2167-4.1375-1.3069-3.6058QC'd by SIGMA
Inactive00041.5831-1.474-0.8986-0.7711-0.1770.65650.5251.14681.4817-0.2959-0.56131.53661.5831QC'd by SIGMA
Inactive00040.51720.14431.6351.35692.2615-1.4225-0.7326-1.01890.1394-0.79210.3889-1.01320.5172QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-cyp2c9
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; cytochrome P450 enzyme and luciferin substrate or buffer only, white solid-bottom Greiner plate.
2; Compounds and control; 16 nL; Kalypsis pintool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 15 min; room temperature.
4; Reagent; 2 uL; nicotinamide adenine dinucleotide phosphate (NADPH).
5; Incubation; 30 - 45 min; room temperature in the dark.
6; Reagent; 4 uL; P450-Glo assay detection reagent.
7; Centrifuge; 1000 RPM; 15 seconds.
8; Incubation; 30 min; room temperature.
9; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. A 2 uL mixture of corresponding enzymes and luciferin substrate (final concentrations CYP enzyme-specific and pro-luciferin substrate-specific) or minus-enzyme (assay buffer conditions supplied by the manufacturer for respective enzyme isoform; typically, 100 mM KPO4) and luciferin substrate were dispensed using a BioRAPTR FRD (Beckman Coulter, Brea, CA) into columns of a 1536-well white solid-bottom medium binding plate (Greiner Bio-One, Monroe, NC). Five isoforms of cytochrome P450 were used (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).
2. Substances (final concentrations of most substances ranged from 19.5 nM to 39.8 uM) and controls (CYP-specific) were transferred (16 nL) via pintool (Wako Automation, Richmond, VA). Intraplate controls furafylline (CYP1A2), sulfaphenazole (CYP2C9), ketoconazole (CYP2C19), quinidine (CYP2D6), and ketoconazole (CYP3A4) were used correspondingly.
3. Assay plates were incubated at room temperature for 15 min.
4-5. Two uL of reduced nicotinamide adenine dinucleotide phosphate (NADPH) regeneration solution (final concentration 1x) was dispensed to initiate the reaction, which then proceeded for 30-45 min (RT, protected from light), allowing NADP+ to convert to NADPH, which then serves as the electron source for the CYP oxidative reactions leading to the pro-luciferin substrate to convert to D-luciferin.
6-8. Next, 4 uL of reconstituted luciferin detection reagent was dispensed to allow for D-luciferin to be converted to light via luciferase reaction. Samples were centrifuged for 15 s at 1000 rpm (233 g) to remove bubbles, followed by an RT incubation for 30 min.
9. Plates were then read for luminescence intensity on a ViewLux detector (PerkinElmer; Waltham, MA).

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003320000 uMActivity at 0.0009960000 uMActivity at 0.00191 uMActivity at 0.00299 uMActivity at 0.00678 uMActivity at 0.00903 uMActivity at 0.025 uMActivity at 0.039 uMActivity at 0.081 uMActivity at 0.162 uMActivity at 0.263 uMActivity at 0.702 uMActivity at 1.291 uMActivity at 2.222 uMActivity at 4.274 uMActivity at 7.106 uMActivity at 18.80 uMActivity at 34.14 uMActivity at 58.33 uMActivity at 103.6 uMActivity at 207.7 uMActivity at 483.1 uMActivity at 966.3 uMActivity at 1932.0 uMActivity at 3487.5 uMActivity at 3920.0 uMCompound QC
Inhibitor4.735595.33784Complete curve; high efficacy-5.32461.24750.9659-87.8377.5-1.10 0 0 0 0 0 0 0 0 0 0 0-82.56040.38896.574412.223324.4435-1.31673.74164.8455-2.6702-16.3026-50.9969-74.6078-82.5604QC'd by NCI-NPB
Inhibitor3.761584.422484Complete curve; high efficacy-5.42463.19250.9972-81.92242.5-1.10 0 0 0 0 0 0 0 0 0 0 0-81.94953.52382.37864.0946-0.30146.043-0.30533.23920.154-10.3105-70.6122-79.9178-81.9495QC'd by NCI-NPB
Inhibitor199.526289.630684Complete curve; high efficacy-3.71.88510.9793-88.63061-1.10 0 0 0 0 0 0 0 0 0 0 0-86.43860.9068-5.7094-7.3528-3.239711.0824-0.9846-23.8153-55.0577-74.146-81.7902-86.8928-86.4386QC'd by Spectrum Chemical
Inhibitor316.227881.332184Complete curve; high efficacy-3.54.95490.9609-81.33210-1.10 0 0 0 0 0 0 0 0 0 0 1-5.5896-7.0092-12.86450.6673-6.43717.95-0.827812.5297-9.0915-71.6261-79.94-81.8703-5.5896QC'd by Spectrum Chemical
Inhibitor251.188683.724884Complete curve; high efficacy-3.62.25260.987-92.2996-8.5748-1.10 0 0 0 0 0 0 0 0 0 0 0-92.1154-17.3126-14.9721-3.8123-11.8221-7.791-14.2527-18.9216-45.6328-79.707-89.6672-91.1315-92.1154QC'd by Spectrum Chemical
Inhibitor6.6891102.100483Complete curve; high efficacy-5.174610.9808-92.60049.5-1.10 0 0 0 0 0 0 0 0 0 0 0-81.291612.12829.060517.69918.18593.16619.61063.3846-6.5145-11.7006-35.6026-72.5097-81.2916QC'd by NCI-NPB
Inhibitor8.42187.858683Complete curve; high efficacy-5.07461.96730.9547-87.85860-1.10 0 0 0 0 0 0 0 0 0 0 0-81.33234.36061.36280.5146-13.7070.54811.173-5.5134-4.42188.3456-33.6622-76.6742-81.3323QC'd by NCI-NPB
Inhibitor11.220288.387482Complete curve; high efficacy-4.952.04370.9775-88.8874-0.5-1.10 0 0 0 0 0 0 0 0 0 0 0-82.3574-10.18285.2089-2.83642.7183-6.77551.70352.5025-1.2315-15.5091-39.8212-67.3151-82.3574QC'd by Microsource
Inhibitor9.448683.102882Complete curve; high efficacy-5.02461.82650.9722-87.1028-4-1.10 0 0 0 0 0 0 0 0 0 0 0-80.3809-6.336-6.1977-1.9112-10.4594-3.4041-1.8276-5.2582-9.38521.5867-34.5198-67.3761-80.3809QC'd by NCI-NPB
Inhibitor9.448687.226982Complete curve; high efficacy-5.02461.96730.9715-88.2269-1-1.10 0 0 0 0 0 0 0 0 0 0 0-81.23251.08874.2213-4.36841.0494-2.308-2.6107-8.2751-7.08434.4831-30.7298-77.1984-81.2325QC'd by NCI-NPB
Inhibitor1088.041482Complete curve; high efficacy-52.12110.9961-88.5414-0.5-1.10 0 0 0 0 0 0 0 0 0 0 0-89.576-0.81931.3824-1.3659-5.1219-0.8424-7.8264-21.4067-55.9088-71.982-87.2074-89.9811-89.576QC'd by USP
Inhibitor12.589383.045882Complete curve; high efficacy-4.92.78680.9896-89.7236-6.6778-1.10 0 0 1 0 0 0 0 0 0 0 0-90.084-2.6005-16.2507-6.5265-42.052-2.2315-7.1845-14.9785-50.2293-75.7589-88.7761-88.7385-90.084QC'd by USP
Inhibitor10.601577.589562Complete curve; partial efficacy-4.97462.72020.9872-76.08951.5-1.20 0 0 0 0 0 0 0 0 0 0 0-76.74121.18384.00641.03362.6764-0.88993.5689-4.3632-0.07857.4706-15.0756-62.1502-76.7412QC'd by NCI-NPB
Inhibitor2818.3829104.91351Partial curve; high efficacy-2.552.25260.7711-109.4745-4.5615-2.10 0 0 0 0 0 0 0 0 0 0 0-82.9352-7.4642-19.7285-7.1104-33.0346-5.657-7.6737-2.4461-16.7261-0.4679-15.5712-34.0531-82.9352QC'd by Spectrum Chemical
Inhibitor2818.3829105.881951Partial curve; high efficacy-2.553.990.9095-110.8958-5.0138-2.10 0 0 0 0 0 0 0 0 0 0 0-88.0125-3.5003-7.9235-10.2901-25.7271-3.4172-0.8449-4.6203-14.0792-6.2779-7.2163-26.2475-88.0125QC'd by USP
Inhibitor13.346484.886342Partial curve; partial efficacy-4.87461.98870.9719-82.38632.5-2.20 0 0 0 0 0 0 0 0 0 0 0-78.4095.60472.58423.1575-2.56934.23911.15492.401-6.589510.6118-16.4029-54.5959-78.409QC'd by NCI-NPB
Inhibitor11.89591.444242Partial curve; high efficacy-4.92461.69240.9808-86.44425-2.10 0 0 0 0 0 0 0 0 0 0 0-81.20359.56712.5743.116-2.90136.38556.11942.64997.43567.7645-22.8064-57.6803-81.2035QC'd by NCI-NPB
Inhibitor1074.976642Partial curve; high efficacy-52.72020.9205-81.6839-6.7073-2.10 0 0 0 0 0 0 0 0 0 0 0-85.0874-8.3248-6.0352-24.268-4.7094-2.5133-4.4354-7.2367-2.2561-7.9932-54.3311-61.0227-85.0874QC'd by MedChem Express
Inhibitor14.1254103.190142Partial curve; high efficacy-4.851.41630.9468-102.69010.5-2.10 0 0 0 0 0 0 0 0 0 0 0-90.0793.6155-6.618-6.3008-1.16783.34692.59786.5816-1.1231-27.9533-43.367-52.7304-90.079QC'd by MedChem Express
Inhibitor112.201876.156842Partial curve; partial efficacy-3.954.95490.9761-76.6568-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0-72.3674-0.4459-0.97512.9006-8.27-2.5471.43880.967-3.8753-0.2713.5751-26.4799-72.3674QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-cyp2d6
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; cytochrome P450 enzyme and luciferin substrate or buffer only, white solid-bottom Greiner plate.
2; Compounds and control; 16 nL; Kalypsis pintool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 15 min; room temperature.
4; Reagent; 2 uL; nicotinamide adenine dinucleotide phosphate (NADPH).
5; Incubation; 30 - 45 min; room temperature in the dark.
6; Reagent; 4 uL; P450-Glo assay detection reagent.
7; Centrifuge; 1000 RPM; 15 seconds.
8; Incubation; 30 min; room temperature.
9; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. A 2 uL mixture of corresponding enzymes and luciferin substrate (final concentrations CYP enzyme-specific and pro-luciferin substrate-specific) or minus-enzyme (assay buffer conditions supplied by the manufacturer for respective enzyme isoform; typically, 100 mM KPO4) and luciferin substrate were dispensed using a BioRAPTR FRD (Beckman Coulter, Brea, CA) into columns of a 1536-well white solid-bottom medium binding plate (Greiner Bio-One, Monroe, NC). Five isoforms of cytochrome P450 were used (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).
2. Substances (final concentrations of most substances ranged from 19.5 nM to 39.8 uM) and controls (CYP-specific) were transferred (16 nL) via pintool (Wako Automation, Richmond, VA). Intraplate controls furafylline (CYP1A2), sulfaphenazole (CYP2C9), ketoconazole (CYP2C19), quinidine (CYP2D6), and ketoconazole (CYP3A4) were used correspondingly.
3. Assay plates were incubated at room temperature for 15 min.
4-5. Two uL of reduced nicotinamide adenine dinucleotide phosphate (NADPH) regeneration solution (final concentration 1x) was dispensed to initiate the reaction, which then proceeded for 30-45 min (RT, protected from light), allowing NADP+ to convert to NADPH, which then serves as the electron source for the CYP oxidative reactions leading to the pro-luciferin substrate to convert to D-luciferin.
6-8. Next, 4 uL of reconstituted luciferin detection reagent was dispensed to allow for D-luciferin to be converted to light via luciferase reaction. Samples were centrifuged for 15 s at 1000 rpm (233 g) to remove bubbles, followed by an RT incubation for 30 min.
9. Plates were then read for luminescence intensity on a ViewLux detector (PerkinElmer; Waltham, MA).

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003320000 uMActivity at 0.0009960000 uMActivity at 0.00191 uMActivity at 0.00299 uMActivity at 0.00678 uMActivity at 0.00903 uMActivity at 0.025 uMActivity at 0.039 uMActivity at 0.081 uMActivity at 0.162 uMActivity at 0.263 uMActivity at 0.702 uMActivity at 1.291 uMActivity at 2.222 uMActivity at 4.274 uMActivity at 7.106 uMActivity at 18.80 uMActivity at 34.14 uMActivity at 58.33 uMActivity at 103.6 uMActivity at 207.7 uMActivity at 483.1 uMActivity at 966.3 uMActivity at 1932.0 uMActivity at 3487.5 uMActivity at 3920.0 uMCompound QC
Inhibitor251.188679.028784Complete curve; high efficacy-3.61.82650.9681-83.8205-4.7919-1.10 0 0 0 0 0 0 0 0 0 0 0-80.81-3.5801-8.4994-13.1278-19.3755-0.6599-4.8562-19.8587-47.1855-69.3997-78.4311-80.2799-80.81QC'd by Spectrum Chemical
Inhibitor5.961686.131483Complete curve; high efficacy-5.22461.28760.9983-84.63141.5-1.10 0 0 0 0 0 0 0 0 0 0 0-80.21422.67031.05721.68663.23122.72650.1761-1.7099-5.2312-16.612-42.505-70.4533-80.2142QC'd by NCI-NPB
Inhibitor4.220557.619663Complete curve; partial efficacy-5.37461.34430.9883-66.9809-9.3614-1.20 0 0 0 0 0 0 0 0 0 0 0-67.0885-13.0738-11.9087-6.5511-6.6688-10.7137-10.1156-8.6562-11.7121-27.7496-46.4977-57.8652-67.0885QC'd by NCI-NPB
Inhibitor2511.8864101.354849Partial curve; partial efficacy-2.62.40640.9541-99.35482-2.20 0 0 0 0 0 0 0 0 0 0 0-75.268812.45689.68711.30223.5613-0.9719-3.1468-4.5266-4.53270.1067-6.6348-34.1586-75.2688QC'd by SIGMA
Inhibitor11.89571.870542Partial curve; partial efficacy-4.92461.50950.9954-86.0273-14.1568-2.20 0 0 0 0 0 0 0 0 0 0 0-80.1804-13.8455-15.2867-15.6556-16.3131-11.7973-11.8007-15.0896-14.6918-17.2314-35.9377-62.9132-80.1804QC'd by NCI-NPB
Inhibitor112.201892.474242Partial curve; partial efficacy-3.952.58840.9351-85.47427-2.20 0 0 0 0 0 0 0 0 0 0 0-67.617912.87815.10556.356719.03663.12963.2625-0.1504-1.10971.234-0.7186-31.6066-67.6179QC'd by Spectrum Chemical
Inhibitor29.87987.411440Partial curve; partial efficacy-4.52462.40640.9824-87.41140-2.20 0 0 0 0 0 0 0 0 0 0 0-73.039-0.80412.7822-5.223-4.3191-0.18041.37470.9545-2.44264.6835-0.3369-24.195-73.039QC'd by NCI-NPB
Inhibitor125.892552.416122Partial curve; partial efficacy-3.94.95490.9811-52.9161-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0-48.99643.48180.0034-3.0184-1.50070.8932-2.65030.75980.35441.2706-2.5612-14.0337-48.9964QC'd by Spectrum Chemical
Inhibitor112.201873.239322Partial curve; partial efficacy-3.952.30310.9136-68.73934.5-2.20 0 0 0 0 0 0 0 0 0 0 0-54.340214.139216.28126.69394.32510.51731.4863-1.9392-2.1982-0.1026-4.5238-26.5164-54.3402QC'd by USP
Inhibitor112.201856.879322Partial curve; partial efficacy-3.951.75290.9715-57.3793-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0-43.46923.14392.5275-1.0499-1.7518-0.18750.1457-4.0305-5.2319-4.7092-10.3309-23.3943-43.4692QC'd by USP
Inhibitor14.125483.576521Partial curve; partial efficacy-4.851.41630.9587-77.57656-2.20 0 0 0 0 0 0 0 0 0 0 0-64.647117.342512.10444.52575.05772.17830.5847-1.1319-4.1561-8.749-20.7622-48.1414-64.6471QC'd by Microsource
Inhibitor21.152753.0721Partial curve; partial efficacy-4.67461.55790.9458-61.1967-8.1267-2.20 0 0 0 0 0 0 0 0 0 0 0-53.6813-14.2925-11.4589-3.4389-6.3311-10.7563-8.5617-3.4588-5.4969-8.8392-17.0974-30.5786-53.6813QC'd by NCI-NPB
Inhibitor18.852462.190121Partial curve; partial efficacy-4.72462.40640.9698-64.6901-2.5-2.20 0 0 0 0 0 0 0 0 0 0 0-61.75010.1415-3.4634-7.5294-7.80212.11840.4924-4.6573-4.11681.0511-7.2992-33.7872-61.7501QC'd by NCI-NPB
Inhibitor18.852452.546221Partial curve; partial efficacy-4.72462.18760.9938-58.4717-5.9255-2.20 0 0 0 0 0 0 0 0 0 0 0-54.6034-6.5939-7.6323-6.0503-4.9212-5.1993-5.8188-6.767-7.8207-4.1046-11.6764-32.6908-54.6034QC'd by NCI-NPB
Inhibitor15.848948.089721Partial curve; partial efficacy-4.82.40640.9753-50.0897-2-2.20 0 0 0 0 0 0 0 0 0 0 0-49.10751.1072-0.1969-0.2926-5.8248-2.5517-0.5357-1.4626-2.4495-7.5371-13.5797-29.6291-49.1075QC'd by Selleck
Inhibitor0.070841.610321Complete curve; partial efficacy-7.152.72020.9673445.6103-1.21 0 0 0 0 0 0 0 0 0 0 05.23275.009542.393219.857213.06842.70764.47843.11184.51874.10632.72144.1515.232QC'd by Microsource
Inhibitor112.201848.925521Partial curve; partial efficacy-3.952.24810.8363-42.92556-2.20 0 0 0 0 0 0 0 0 0 0 0-33.705715.869413.29635.31659.2451-0.410.3331.55151.72952.1986-2.2982-10.7318-33.7057QC'd by SIGMA
Inhibitor56.234191.38321Partial curve; partial efficacy-4.250.80.8729-69.38322-2.20 0 0 0 0 0 0 0 0 0 0 0-50.853832.729821.532418.943624.47662.799-0.37924.20355.15311.1661-12.4345-42.6984-50.8538QC'd by USP
Inhibitor0.063154.834820Complete curve; partial efficacy-7.23.1320.7923-1.002753.8321-1.20 0 0 0 0 0 0 0 0 0 0 0-10.834239.660169.13354.71625.33693.69931.44370.15850.45474.19780.2926-3.6311-10.8342QC'd by Selleck
Inhibitor0.063146.415120Complete curve; partial efficacy-7.22.72020.94510.387946.803-1.20 0 0 0 0 0 0 0 0 0 0 04.488249.03240.772911.38388.96320.7683-3.3873-0.38740.71230.0424-5.09345.83614.4882QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: DSHEA-v1-KB-3-1-CTG
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; KB-3-1 cells, white solid-bottom tissue treated Greiner plate.
2; Incubation; 4 hrs; 37C, 95% humidity, 5% CO2.
3; Compounds and control; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
4; Incubation; 72 hrs; 37C, 95% humidity, 5% CO2.
5; Reagent; 2.5 uL; CellTiter-Glo.
6; Centrifuge; 1000 RPM; 15 seconds.
7; Incubation; 30 min; room temperature.
8; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Cell line KB-3-1 and its colchicine-selected, P-gp-overexpressing subline KB-8-5-11 were maintained in DMEM (Thermofisher catalog #11965) with 10% FBS and 1% penicillin/streptomycin at 37C in 5% CO2. For the screen, assay medium was identical to culture medium. Briefly, 5 uL of cells at 1 x 105 cells/mL (500 cells/well) were dispensed into a 1536-well white solid-bottom tissue treated plate (Greiner Bio-One) using a Multidrop Combi dispenser.
2. Plates were incubated at 37C, 95% humidity, 5% CO2 for ~4 hours to allow for cell attachment.
3. Compounds and intraplate control (Bortezomib; final concentration range 228 pM - 7.5 uM) were transferred (16 nL) via pintool (Wako Automation), for a final concentration of 15.6 nM - 30.0 uM (most substances).
4. Plates were incubated for ~72 hours at 37C, 95% humidity, 5% CO2.
5. Plates were then dispensed with 2.5 uL of CellTiter-Glo.
6. The assay plates were centrifuged for 15 seconds at 1,000 RPM's.
7. The plates were incubated for 30-minute at room temperature.
8. Luminescence intensity was detected using a PerkinElmer ViewLux microplate reader.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic (inhibition of viability) compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class (CRC) = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
3. In addition, activity in the P-gp counter screens is defined as a sample yielding a CRC of -1.1, -1.2, -2.1, or -2.2 in the KB-3-1 assay and selective (or potentially interacting with P-gp) if it has an IC50 ratio of >5 vs KB-8-5-11 (if activity was observed).
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002540000 uMActivity at 0.0007610000 uMActivity at 0.00146 uMActivity at 0.00228 uMActivity at 0.00518 uMActivity at 0.00689 uMActivity at 0.019 uMActivity at 0.030 uMActivity at 0.062 uMActivity at 0.124 uMActivity at 0.201 uMActivity at 0.536 uMActivity at 0.983 uMActivity at 1.693 uMActivity at 3.263 uMActivity at 5.424 uMActivity at 14.38 uMActivity at 26.09 uMActivity at 44.54 uMActivity at 79.09 uMActivity at 158.8 uMActivity at 368.8 uMActivity at 738.4 uMActivity at 1478.8 uMActivity at 2661.4 uMActivity at 2990.0 uMCompound QC
Inhibitor27.277244.278810Single point of activity-4.56421.98870.7665-44.7788-0.5-30 0 0 0 0 0 0 0 0 0 0 0-33.589-1.64246.7747-2.0366-3.4301-2.7811.1315-0.7743-0.417-9.8655-5.7016-9.1282-33.589QC'd by NCI-NPB
Inhibitor34.3446.898610Single point of activity-4.46424.95490.7878-47.8986-1-30 0 0 0 0 0 0 0 0 0 0 0-38.0147-9.36064.92333.4993-6.4011-1.9211-0.97160.05814.6955-10.89445.95540.3047-38.0147QC'd by NCI-NPB
Inhibitor25.118962.533610Single point of activity-4.63.51170.8055-52.033610.5-30 0 0 0 0 0 0 0 0 0 0 0-38.64169.599417.994415.201910.50920.868811.798617.4356-0.719810.93937.83349.9795-38.6416QC'd by DC Chemicals
Inhibitor2511.8864101.710310Single point of activity-2.63.990.7912-105.7103-4-30 0 0 0 0 0 0 0 0 0 0 0-80.0836-3.6429-17.4873-7.4171-14.3139-8.5427-10.134-1.1941-14.91670.6601-3.26538.6203-80.0836QC'd by Spectrum Chemical
Inhibitor2511.8864109.515110Single point of activity-2.63.92950.9288-108.01511.5-30 0 0 0 0 0 0 0 0 0 0 0-81.8296-1.25335.29856.2525-7.23613.35051.00016.0868-1.8388-2.6316-1.03491.8872-81.8296QC'd by Spectrum Chemical
Inactive0004-2.87-2.93836.4118.8105-1.3523-4.08296.126710.453-0.7495-2.031610.62352.8522-2.87QC'd by NIEHS
Inactive0004-4.19312.16139.138525.26934.5704-1.925615.41589.80237.57045.69099.20384.1989-4.1931QC'd by NIEHS
Inactive0-6.554.95490.36644.5-4.691140 0 0 0 0 0 0 0 0 0 0 05.0429-0.6683-8.9093-1.8002-6.1534-4.17999.320610.9819-5.5553-4.57713.78823.92075.0429QC'd by Labotest
Inactive0004-0.0691-3.012-1.7805-5.9791-0.895-0.9156-2.5864-8.6294-2.43823.6731-4.5631-2.64-0.0691QC'd by Microsource
Inactive00046.4354-2.09545.8533.3389-6.43517.33073.818410.4878-3.542511.83954.090313.1936.4354QC'd by SigmaAldrich
Inactive0004-8.46270.19868.60028.8732-1.21167.23888.817427.1363.6351.075812.293611.5609-8.4627QC'd by FLUKA
Inactive0004-6.26-8.49412.9725-2.2517-10.3171-9.7818-13.3139-1.3284-8.3056-8.66712.25912.5566-6.26QC'd by Timtec
Inactive0-5.750.40.441-31740 0 0 0 0 0 0 0 0 0 0 112.56659.214922.825714.45548.42726.19179.057813.87574.47538.92341.4773.30512.5665QC'd by ASDI
Inactive00047.833911.1766.23769.39990.01923.73693.365414.08278.75016.95520.76523.71057.8339QC'd by SigmaAldrich
Inactive0-5.554.95490.327-1.434513.540 0 0 0 0 0 0 0 0 0 0 0-7.7457-3.374524.183829.62461.75915.028910.027517.9632-2.2393-10.85957.97818.5714-7.7457QC'd by SigmaAldrich
Inactive0-5.41.75290.58335-6.440740 0 0 0 0 0 0 0 0 0 0 1-4.7695-7.7112-4.7869-0.7306-8.9562-13.2839-4.1819-1.2629-2.87360.75079.24431.1254-4.7695QC'd by Enamine
Inactive0-5.14.44950.50729.5-8.234140 0 0 0 0 0 0 0 0 0 0 10.3085-2.2647-2.7047-2.7527-10.2147-26.0284-10.0346-1.3339-9.3699-1.10239.0049.25880.3085QC'd by Enamine
Inactive0-4.410.7212-28.9086-0.540 0 0 0 0 0 0 0 0 0 0 0-20.7571-2.51345.19340.9278-3.3845-3.1564-2.1547-1.1264-1.2554-11.2775-5.0206-8.3718-20.7571QC'd by Enamine
Inactive0-5.64.95490.409-1.1734940 0 0 0 0 0 0 0 0 0 0 0-10.97793.117916.779810.67048.10933.672310.27278.0768-0.882-5.86895.53088.0025-10.9779QC'd by SIGMA
Inactive0004-16.4295-9.71666.05465.4757-4.5626-6.42348.1701-3.3753-8.2701-12.8443-1.2306-0.8301-16.4295QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-cyp2C19
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; cytochrome P450 enzyme and luciferin substrate or buffer only, white solid-bottom Greiner plate.
2; Compounds and control; 16 nL; Kalypsis pintool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 15 min; room temperature.
4; Reagent; 2 uL; nicotinamide adenine dinucleotide phosphate (NADPH).
5; Incubation; 30 - 45 min; room temperature in the dark.
6; Reagent; 4 uL; P450-Glo assay detection reagent.
7; Centrifuge; 1000 RPM; 15 seconds.
8; Incubation; 30 min; room temperature.
9; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. A 2 uL mixture of corresponding enzymes and luciferin substrate (final concentrations CYP enzyme-specific and pro-luciferin substrate-specific) or minus-enzyme (assay buffer conditions supplied by the manufacturer for respective enzyme isoform; typically, 100 mM KPO4) and luciferin substrate were dispensed using a BioRAPTR FRD (Beckman Coulter, Brea, CA) into columns of a 1536-well white solid-bottom medium binding plate (Greiner Bio-One, Monroe, NC). Five isoforms of cytochrome P450 were used (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).
2. Substances (final concentrations of most substances ranged from 19.5 nM to 39.8 uM) and controls (CYP-specific) were transferred (16 nL) via pintool (Wako Automation, Richmond, VA). Intraplate controls furafylline (CYP1A2), sulfaphenazole (CYP2C9), ketoconazole (CYP2C19), quinidine (CYP2D6), and ketoconazole (CYP3A4) were used correspondingly.
3. Assay plates were incubated at room temperature for 15 min.
4-5. Two uL of reduced nicotinamide adenine dinucleotide phosphate (NADPH) regeneration solution (final concentration 1x) was dispensed to initiate the reaction, which then proceeded for 30-45 min (RT, protected from light), allowing NADP+ to convert to NADPH, which then serves as the electron source for the CYP oxidative reactions leading to the pro-luciferin substrate to convert to D-luciferin.
6-8. Next, 4 uL of reconstituted luciferin detection reagent was dispensed to allow for D-luciferin to be converted to light via luciferase reaction. Samples were centrifuged for 15 s at 1000 rpm (233 g) to remove bubbles, followed by an RT incubation for 30 min.
9. Plates were then read for luminescence intensity on a ViewLux detector (PerkinElmer; Waltham, MA).

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003320000 uMActivity at 0.0009960000 uMActivity at 0.00191 uMActivity at 0.00299 uMActivity at 0.00678 uMActivity at 0.00903 uMActivity at 0.025 uMActivity at 0.039 uMActivity at 0.081 uMActivity at 0.162 uMActivity at 0.263 uMActivity at 0.702 uMActivity at 1.291 uMActivity at 2.222 uMActivity at 4.274 uMActivity at 7.106 uMActivity at 18.80 uMActivity at 34.14 uMActivity at 58.33 uMActivity at 103.6 uMActivity at 207.7 uMActivity at 483.1 uMActivity at 966.3 uMActivity at 1932.0 uMActivity at 3487.5 uMActivity at 3920.0 uMCompound QC
Inhibitor3.3525102.746485Complete curve; high efficacy-5.47460.80.983-102.24640.5-1.10 0 0 0 0 0 0 0 0 0 0 0-91.12872.306-1.2532-1.49430.8104-4.068-2.6099-6.0569-33.5631-34.424-64.7066-85.7903-91.1287QC'd by NCI-NPB
Inhibitor316.2278101.242785Complete curve; high efficacy-3.52.25260.9781-105.2427-4-1.10 0 0 0 0 0 0 0 0 0 0 0-101.9794-1.1456-7.963-17.44351.7259-2.1173-10.3243-23.4021-34.1145-85.4858-97.8186-101.304-101.9794QC'd by Spectrum Chemical
Inhibitor3.548186.580584Complete curve; high efficacy-5.454.95490.9652-84.58052-1.10 0 0 0 0 0 0 0 0 0 1 0-72.8565-5.27272.3459.0259-0.6291-3.8292-1.31557.96-1.4856-78.8166-89.7882-39.7605-72.8565QC'd by SigmaAldrich
Inhibitor3.548187.675384Complete curve; high efficacy-5.454.95490.9749-87.17530.5-1.10 0 0 0 0 0 0 0 0 0 0 0-85.85712.13483.83610.8211-0.0339-3.1913-1.0786-4.0482-1.9757-86.6805-89.1363-75.9326-85.8571QC'd by Microsource
Inhibitor3.981186.529784Complete curve; high efficacy-5.44.0950.9452-82.02974.5-1.10 0 0 0 0 0 0 0 0 0 0 0-83.38566.21496.57340.2882-3.684412.94177.20861.0503-4.6284-61.6505-58.1178-99.0697-83.3856QC'd by Selleck
Inhibitor3.981181.100184Complete curve; high efficacy-5.44.95490.9816-84.6085-3.5084-1.10 0 0 0 0 0 0 0 0 0 0 0-89.8179-2.0956-3.978-8.4074-5.5058-2.8308-6.1578-1.6736-1.8783-71.6576-81.1791-76.2508-89.8179QC'd by SIGMA
Inhibitor5.961697.842284Complete curve; high efficacy-5.22461.1110.9952-99.8422-2-1.10 0 0 0 0 0 0 0 0 0 0 0-91.9358-5.4966-3.651-4.1563-1.3933-0.7010.6512-1.1957-13.4032-24.8064-53.2758-80.4228-91.9358QC'd by NCI-NPB
Inhibitor5.313387.433884Complete curve; high efficacy-5.27461.55790.9856-91.4636-4.0298-1.10 0 0 0 0 0 0 0 0 0 0 0-91.2811-7.5271-10.81-0.0248-11.2666-5.6041-2.8161-0.514-5.0966-22.7221-54.5554-79.4265-91.2811QC'd by NCI-NPB
Inhibitor5.961693.894584Complete curve; high efficacy-5.22461.34430.9807-96.8945-3-1.10 0 0 0 0 0 0 0 0 0 0 0-91.75610.8839-1.47861.9048-9.3198-0.5097-2.7556-4.7098-18.8872-16.5117-53.5984-82.2597-91.7561QC'd by NCI-NPB
Inhibitor3.548183.821584Complete curve; high efficacy-5.454.95490.9727-85.8215-2-1.10 0 0 0 0 0 0 0 0 0 0 0-85.23515.9743-6.0593-10.7353-6.67492.2245-1.7138-7.3619-2.9683-78.2826-77.1017-91.1056-85.2351QC'd by Prestwick
Inhibitor3.548190.584284Complete curve; high efficacy-5.454.95490.9796-91.0842-0.5-1.10 0 0 0 0 0 0 0 0 0 0 0-88.5050.7758-1.6361-0.5616-0.825-2.8315-2.5195-4.8091-1.3245-89.957-84.0437-90.9024-88.505QC'd by Enzo
Inhibitor3.548180.855584Complete curve; high efficacy-5.454.95490.969-80.85550-1.10 0 0 0 0 0 0 0 0 0 0 0-88.0779-3.9801-0.85695.81571.4652-2.5685-0.0897-4.5454-4.6737-78.7127-78.1174-67.0199-88.0779QC'd by Microsource
Inhibitor6.3096106.044184Complete curve; high efficacy-5.21.62660.9986-105.54410.5-1.10 0 0 0 0 0 0 0 0 0 0 0-97.7261.2222-0.49540.36910.1088-2.5527-2.086-4.3081-17.834-40.913-70.4348-89.5083-97.726QC'd by Analyticon
Inhibitor3.981190.260984Complete curve; high efficacy-5.44.95490.9878-88.76091.5-1.10 0 0 0 0 0 0 0 0 0 0 0-98.62325.3874-4.27980.59041.39665.2468-2.64992.4172-4.0302-64.5359-83.0562-83.4938-98.6232QC'd by Analyticon
Inhibitor3.548189.87884Complete curve; high efficacy-5.454.95490.985-91.878-2-1.10 0 0 0 0 0 0 0 0 0 0 0-89.38734.2288-6.7834-3.7421-4.6625-1.9858-4.5484-3.1235-5.2663-86.7452-86.1651-92.247-89.3873QC'd by Adooq
Inhibitor199.5262108.103684Complete curve; high efficacy-3.71.46410.9866-110.3578-2.2542-1.10 0 0 0 0 0 0 0 0 0 0 0-101.6186-1.0451-6.0689-4.6963-5.7733-5.9273-13.6814-29.9616-53.6886-95.8559-100.2467-101.3383-101.6186QC'd by SIGMA
Inhibitor251.188697.971584Complete curve; high efficacy-3.62.40640.9946-97.97150-1.10 0 0 0 0 0 0 0 0 0 0 0-100.17544.18842.98280.6609-4.5763-0.5886-3.3506-14.901-40.8887-84.4964-92.9996-92.3084-100.1754QC'd by Spectrum Chemical
Inhibitor158.489398.922884Complete curve; high efficacy-3.82.18760.9987-101.8223-2.8995-1.10 0 0 0 0 0 0 0 0 0 0 0-102.2312-1.1663-5.6099-3.7621-1.4466-4.198-14.1356-40.8501-71.5839-95.3759-99.8113-101.7991-102.2312QC'd by Spectrum Chemical
Inhibitor5.313388.083483Complete curve; high efficacy-5.27463.92950.9848-86.58341.5-1.10 0 0 0 0 0 0 0 0 0 0 0-90.1918.8165-3.6372.09720.26247.4702-0.0049-0.3319-5.96483.4102-58.3652-83.0688-90.191QC'd by NCI-NPB
Inhibitor9.448694.871183Complete curve; high efficacy-5.02461.88510.957-98.8711-4-1.10 0 0 0 0 0 0 0 0 0 0 0-91.0415-0.168-4.1666-8.9712-15.70771.1521-2.6389-6.2635-14.64782.6122-34.6086-82.8488-91.0415QC'd by NCI-NPB
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-cyp3a4
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; cytochrome P450 enzyme and luciferin substrate or buffer only, white solid-bottom Greiner plate.
2; Compounds and control; 16 nL; Kalypsis pintool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 15 min; room temperature.
4; Reagent; 2 uL; nicotinamide adenine dinucleotide phosphate (NADPH).
5; Incubation; 30 - 45 min; room temperature in the dark.
6; Reagent; 4 uL; P450-Glo assay detection reagent.
7; Centrifuge; 1000 RPM; 15 seconds.
8; Incubation; 30 min; room temperature.
9; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. A 2 uL mixture of corresponding enzymes and luciferin substrate (final concentrations CYP enzyme-specific and pro-luciferin substrate-specific) or minus-enzyme (assay buffer conditions supplied by the manufacturer for respective enzyme isoform; typically, 100 mM KPO4) and luciferin substrate were dispensed using a BioRAPTR FRD (Beckman Coulter, Brea, CA) into columns of a 1536-well white solid-bottom medium binding plate (Greiner Bio-One, Monroe, NC). Five isoforms of cytochrome P450 were used (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).
2. Substances (final concentrations of most substances ranged from 19.5 nM to 39.8 uM) and controls (CYP-specific) were transferred (16 nL) via pintool (Wako Automation, Richmond, VA). Intraplate controls furafylline (CYP1A2), sulfaphenazole (CYP2C9), ketoconazole (CYP2C19), quinidine (CYP2D6), and ketoconazole (CYP3A4) were used correspondingly.
3. Assay plates were incubated at room temperature for 15 min.
4-5. Two uL of reduced nicotinamide adenine dinucleotide phosphate (NADPH) regeneration solution (final concentration 1x) was dispensed to initiate the reaction, which then proceeded for 30-45 min (RT, protected from light), allowing NADP+ to convert to NADPH, which then serves as the electron source for the CYP oxidative reactions leading to the pro-luciferin substrate to convert to D-luciferin.
6-8. Next, 4 uL of reconstituted luciferin detection reagent was dispensed to allow for D-luciferin to be converted to light via luciferase reaction. Samples were centrifuged for 15 s at 1000 rpm (233 g) to remove bubbles, followed by an RT incubation for 30 min.
9. Plates were then read for luminescence intensity on a ViewLux detector (PerkinElmer; Waltham, MA).

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003320000 uMActivity at 0.0009960000 uMActivity at 0.00191 uMActivity at 0.00299 uMActivity at 0.00678 uMActivity at 0.00903 uMActivity at 0.025 uMActivity at 0.039 uMActivity at 0.081 uMActivity at 0.162 uMActivity at 0.263 uMActivity at 0.702 uMActivity at 1.291 uMActivity at 2.222 uMActivity at 4.274 uMActivity at 7.106 uMActivity at 18.80 uMActivity at 34.14 uMActivity at 58.33 uMActivity at 103.6 uMActivity at 207.7 uMActivity at 483.1 uMActivity at 966.3 uMActivity at 1932.0 uMActivity at 3487.5 uMActivity at 3920.0 uMCompound QC
Inhibitor5.3133102.96384Complete curve; high efficacy-5.27460.90.9969-105.963-3-1.10 0 0 0 0 0 0 0 0 0 0 0-93.9388-3.6833-1.69860.1288-2.2403-6.7082-6.5244-8.8784-19.6778-32.9221-59.3597-84.0996-93.9388QC'd by NCI-NPB
Inhibitor6.689188.842683Complete curve; high efficacy-5.17461.88510.9649-96.6679-7.8254-1.10 0 0 0 0 0 0 0 0 0 0 0-94.7725-3.9649-10.1379-11.6353-14.1309-3.1878-7.7263-16.7108-23.3167-12.7101-50.5665-88.0662-94.7725QC'd by NCI-NPB
Inhibitor6.689196.037983Complete curve; high efficacy-5.174610.9945-103.1857-7.1478-1.10 0 0 0 0 0 0 0 0 0 0 0-91.4767-6.2048-4.2898-6.5291-7.7954-8.5443-8.1267-10.7167-20.5738-27.8749-52.2482-82.4876-91.4767QC'd by NCI-NPB
Inhibitor5.011980.108483Complete curve; high efficacy-5.32.33320.9356-82.6385-2.5301-1.10 0 0 0 1 0 0 0 0 0 0 0-73.8394-12.5251-26.0344-61.929-84.1697-43.5582-73.1439-81.8175-89.4563-75.5045-84.5399-92.4368-73.8394QC'd by Spectrum Chemical
Inhibitor11.89593.183982Complete curve; high efficacy-4.92463.1320.9924-93.6839-0.5-1.10 0 0 0 0 0 0 0 0 0 0 0-92.3904-3.5838-1.8919-4.2886-2.10891.87435.1641.58032.7509-3.8827-13.3375-78.5161-92.3904QC'd by NCI-NPB
Inhibitor12.589399.680482Complete curve; high efficacy-4.90.80.9775-101.6659-1.9855-1.10 0 0 0 0 0 0 0 0 0 0 0-93.1006-0.8212-5.3139-9.6725-18.4943-13.6918-21.2172-35.7129-62.8841-59.2954-74.9243-85.3233-93.1006QC'd by USP
Inhibitor14.125495.969242Partial curve; high efficacy-4.852.78680.9909-98.9692-3-2.10 0 0 0 0 0 0 0 0 0 0 0-92.1501-0.32292.454-1.1436-1.2898-4.8475-3.5323-3.5592-8.5346-11.553-26.5976-74.0541-92.1501QC'd by Bio Vision
Inhibitor12.5893102.302642Partial curve; partial efficacy-4.91.24750.9736-99.80262.5-2.20 0 0 0 0 0 0 0 0 0 0 0-79.60523.22564.43883.5016-4.03036.7017-0.28970.4913-19.6185-14.4427-42.9104-62.7365-79.6052QC'd by DC Chemicals
Inhibitor125.892568.821442Partial curve; partial efficacy-3.94.95490.9531-70.8214-2-2.20 0 0 0 0 0 0 0 0 0 0 0-69.4328-2.50450.746-11.8103-1.0735-5.50473.72780.07-3.2128-1.35730.1155-14.5339-69.4328QC'd by Spectrum Chemical
Inhibitor22.387289.697741Partial curve; partial efficacy-4.653.06540.9777-88.19771.5-2.20 0 0 0 0 0 0 0 0 0 0 0-75.14981.35682.5314.04811.35520.49562.8303-6.8526-2.78662.98530.5302-34.3864-75.1498QC'd by Enzo
Inhibitor18.8524110.695741Partial curve; high efficacy-4.72460.90.9817-117.6878-6.9921-2.10 0 0 0 0 0 0 0 0 0 0 0-89.9754-4.4124-5.0355-3.7434-10.448-5.3859-7.1355-7.9998-22.4926-19.9316-35.7803-61.0935-89.9754QC'd by NCI-NPB
Inhibitor21.152780.647341Partial curve; partial efficacy-4.67461.10.9501-84.6473-4-2.20 0 0 0 0 0 0 0 0 0 0 0-67.18040.1204-7.8844-1.6098-6.6505-1.0527-10.0428-7.7552-15.2767-6.8764-21.0347-39.5639-67.1804QC'd by NCI-NPB
Inhibitor16.802293.116441Partial curve; high efficacy-4.77461.50950.9854-97.1164-4-2.10 0 0 0 0 0 0 0 0 0 0 0-83.8656-5.8658-0.5611-2.46650.694-7.7796-1.2565-7.1668-9.2764-11.3983-19.829-57.7111-83.8656QC'd by NCI-NPB
Inhibitor14.125474.861741Partial curve; high efficacy-4.852.53340.9904-81.9062-7.0445-2.10 0 0 0 0 0 0 0 0 0 0 0-80.3002-5.9335-9.5024-7.4839-3.3704-8.4709-8.824-7.3144-5.3278-12.9258-27.439-55.5078-80.3002QC'd by Analyticon
Inhibitor15.848975.831941Partial curve; partial efficacy-4.82.40640.9617-79.8319-4-2.20 0 0 0 0 0 0 0 0 0 0 0-83.1582-4.078-2.74981.7121-6.4654-6.7262-6.424-1.0761-10.3315-9.9958-23.1371-45.4924-83.1582QC'd by Analyticon
Inhibitor15.848967.727141Partial curve; partial efficacy-4.82.33320.9724-71.7271-4-2.20 0 0 0 0 0 0 0 0 0 0 0-70.3207-5.7275-4.47161.0622-0.7957-8.0436-8.752-4.7162-9.0663-9.7994-20.1192-44.8651-70.3207QC'd by MedChem Express
Inhibitor14.125480.36841Partial curve; partial efficacy-4.851.24750.9779-80.3680-2.20 0 0 0 0 0 0 0 0 0 0 0-66.97342.91162.7099-1.8949-2.29681.8104-0.5833-8.236-13.8163-15.4864-27.0513-49.7286-66.9734QC'd by DC Chemicals
Inhibitor44.6684116.77741Partial curve; high efficacy-4.351.1110.9953-114.2772.5-2.10 0 0 0 0 0 0 0 0 0 0 0-95.23083.34293.66761.72083.0885-0.5206-2.3063-10.7156-23.9669-31.6427-60.4043-82.5632-95.2308QC'd by USP
Inhibitor35.481383.556740Partial curve; partial efficacy-4.452.78680.9858-86.5567-3-2.20 0 0 0 0 0 0 0 0 0 0 0-77.9639-1.3865-0.3184-5.0818-4.88051.1515-0.0782-4.0494-8.9844-8.3221-13.7596-51.2402-77.9639QC'd by SIGMA
Inhibitor25.118995.404540Partial curve; partial efficacy-4.63.19250.9728-88.40457-2.20 0 0 0 0 0 0 0 0 0 0 0-70.00347.56168.55356.5176-1.079512.02779.70767.64050.635510.86673.899-22.8151-70.0034QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"